How to buy Cytokinetics stock (CYTK)

Cytokinetics is a biotechnology business based in the US. Cytokinetics shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $48.53 – an increase of 4.68% over the previous week. Cytokinetics employs 423 staff and has a trailing 12-month revenue of around $3.2 million.

Our top picks for where to buy Cytokinetics stock

Buy Cytokinetics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cytokinetics stock price (NASDAQ: CYTK)

Use our graph to track the performance of CYTK stocks over time.

Cytokinetics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$48.53
52-week range	$43.21 - $110.25
50-day moving average more info button	$52.42
200-day moving average more info button	$57.33
Wall St. target price	$80.69
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.38

Is it a good time to buy Cytokinetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytokinetics price performance over time

Historical closes compared with the close of $48.95 from 2024-12-23

1 week (2024-12-18)	5.59%
1 month (2024-11-25)	-2.59%
3 months (2024-09-25)	-7.08%
6 months (2024-06-25)	-7.41%

1 year (2023-12-22)	9.75%
2 years (2022-12-23)	7.37%
3 years (2021-12-23)	9.61%
5 years (2019-12-24)	372.95%

Cytokinetics financials

Revenue TTM	$3.2 million
Gross profit TTM	$-146,225,000
Return on assets TTM	-30.13%
Return on equity TTM	-572.15%
Profit margin	0%
Book value	$-0.12
Market Capitalization more info button	$5.5 billion

TTM: trailing 12 months

Cytokinetics share dividends

We're not expecting Cytokinetics to pay a dividend over the next 12 months.

Have Cytokinetics's shares ever split?

Cytokinetics's shares were split on a 1:6 basis on 24 June 2013 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics shares which in turn could have impacted Cytokinetics's share price.

Cytokinetics share price volatility

Over the last 12 months, Cytokinetics's shares have ranged in value from as little as $43.21 up to $110.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics's is 0.783. This would suggest that Cytokinetics's shares are less volatile than average (for this exchange).

Cytokinetics overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. .

Frequently asked questions

null
What percentage of Cytokinetics is owned by insiders or institutions?
Currently 0.536% of Cytokinetics shares are held by insiders and 118.686% by institutions. How many people work for Cytokinetics?
Latest data suggests 423 work at Cytokinetics. When does the fiscal year end for Cytokinetics?
Cytokinetics's fiscal year ends in December. Where is Cytokinetics based?
Cytokinetics's address is: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Cytokinetics's ISIN number?
Cytokinetics's international securities identification number is: US23282W6057 What is Cytokinetics's CUSIP number?
Cytokinetics's Committee on Uniform Securities Identification Procedures number is: 23282W100